Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor ofdihydroorotate dehydrogenase(DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC₅₀values of 2.5 and 2 μM forIgMandIgG, respectively. Laflunimus also is aprostaglandin endoperoxide H synthase (PGHS) -1and-2inhibitor^[1][2].

Ig secretion from mouse splenocytes was induced by lipopolysaccharide (LPS) for 5 days. Laflunimus inhibited the secretion of IgM and IgG with IC₅₀values of 2.5 and 2 μM , respectively. Adding Uridine (50 μ M) increased these values to 70 and 60 μ M, respectively. Laflunimus inhibits LPS-induced kappa light-chain cell surface expression on 70Z/3 cells, a property also reversed by uridine^[1].
Laflunimus (HR325) is more potent than A77 1726 as an inhibitor of PGHS in guinea pig polymorphonuclear leukocytes (IC₅₀= 415 and 4400 nM, respectively) and on isolated ovine PGHS-1 (IC₅₀=64 and 742 μM) and PGHS-2 (IC₅₀=100 and 2766 μM)^[2].

HR325 (50 mg/kg; p.o.; days 14-18 after being injected with SRBC) inhibits the secondary anti-sheep red blood cell (SRBC) antibody response with ID₅₀values of 38 mg/kg^[1].

310.27

Solid

C₁₅H₁₃F₃N₂O₂

147076-36-6

Room temperature in continental US; may vary elsewhere.

DMSO : 50 mg/mL(161.15 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    90%corn oil

  Solubility: ≥ 2.5 mg/mL (8.06 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (8.06 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。